Novartis AG ADR [NYSE: NVS] price plunged by -3.25 percent to reach at -$3.85.
A sum of 4872860 shares traded at recent session while its average daily volume was at 1.58M shares. Novartis AG ADR shares reached a high of $116.325 and dropped to a low of $113.76 until finishing in the latest session at $114.52.
The one-year NVS stock forecast points to a potential upside of 8.69. The average equity rating for NVS stock is currently 2.96, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Novartis AG ADR [NVS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NVS shares is $125.42 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NVS stock is a recommendation set at 2.96. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for Novartis AG ADR shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on February 13, 2025. While these analysts kept the previous recommendation, Morgan Stanley raised their target price to Underweight. The new note on the price target was released on February 12, 2025, representing the official price target for Novartis AG ADR stock.
The Price to Book ratio for the last quarter was 5.28, with the Price to Cash per share for the same quarter was set at 3.69. Price to Free Cash Flow for NVS in the course of the last twelve months was 12.34 with Quick ratio for the last quarter at 0.62.
NVS Stock Performance Analysis:
Novartis AG ADR [NVS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.44. With this latest performance, NVS shares dropped by -3.02% in over the last four-week period, additionally plugging by 15.25% over the last 6 months – not to mention a rise of 17.69% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NVS stock in for the last two-week period is set at 36.95, with the RSI for the last a single of trading hit 2.15, and the three-weeks RSI is set at 1.96 for Novartis AG ADR [NVS]. The present Moving Average for the last 50 days of trading for this stock 116.21, while it was recorded at 118.92 for the last single week of trading, and 109.43 for the last 200 days.
Insight into Novartis AG ADR Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Novartis AG ADR [NVS] shares currently have an operating margin of 31.63% and a Gross Margin at 74.46%. Novartis AG ADR’s Net Margin is presently recorded at 24.89%.
Novartis AG ADR (NVS) Capital Structure & Debt Analysis
According to recent financial data for Novartis AG ADR. ( NVS), the Return on Equity (ROE) stands at 32.82%, highlighting impressive shareholder gains. The Return on Assets (ROA) is 13.61%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Novartis AG ADR’s Return on Invested Capital (ROIC) is 19.49%, showcasing its effectiveness in deploying capital for earnings.
Novartis AG ADR (NVS) Efficiency & Liquidity Metrics
Based on Novartis AG ADR’s (NVS) latest financial statements, the Debt-to-Equity Ratio is 0.78%, indicating its reliance on debt financing relative to shareholder equity.
Novartis AG ADR (NVS) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Novartis AG ADR. (NVS) effectively leverages its workforce, generating an average of $169603.2 per employee. The company’s liquidity position is robust, with a Current Ratio of 0.82% and a Quick Ratio of 0.62%, indicating strong ability to cover short-term liabilities.
NVS Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NVS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Novartis AG ADR go to 7.28%.
Novartis AG ADR [NVS] Institutonal Ownership Details
There are presently around $7.16%, or 7.16% of NVS stock, in the hands of institutional investors. The top three institutional holders of NVS stocks are: DODGE & COX with ownership of 12.24 million shares, which is approximately 0.6019%. PRIMECAP MANAGEMENT CO/CA/, holding 12.18 million shares of the stock with an approximate value of $$1.3 billion in NVS stocks shares; and PRIMECAP MANAGEMENT CO/CA/, currently with $$789.58 million in NVS stock with ownership which is approximately 0.3648%.
